BioScrip, Inc. (NASDAQ:BIOS) has been given an average rating of “Hold” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $3.94.

A number of brokerages recently weighed in on BIOS. Zacks Investment Research downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 14th. SunTrust Banks, Inc. raised shares of BioScrip from a “hold” rating to a “buy” rating and boosted their price target for the stock from $3.25 to $3.75 in a report on Thursday, August 10th. Barrington Research boosted their price target on shares of BioScrip to $3.50 and gave the stock an “outperform” rating in a report on Monday, June 26th. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th.

Shares of BioScrip (BIOS) traded up 4.64% on Friday, reaching $2.93. 3,051,514 shares of the company traded hands. The stock’s market cap is $373.50 million. The stock has a 50 day moving average of $2.89 and a 200 day moving average of $2.14. BioScrip has a 52-week low of $0.98 and a 52-week high of $3.43.

BioScrip (NASDAQ:BIOS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The company had revenue of $218.11 million for the quarter, compared to the consensus estimate of $220.05 million. The business’s revenue was down 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.14) earnings per share. On average, analysts expect that BioScrip will post ($0.55) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “BioScrip, Inc. (BIOS) Receives $3.94 Consensus Target Price from Analysts” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/bioscrip-inc-bios-receives-3-94-consensus-target-price-from-analysts/1530343.html.

In related news, Director Coliseum Capital Management, L sold 886,478 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.80% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its stake in shares of BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock worth $109,000 after buying an additional 25,500 shares in the last quarter. American International Group Inc. boosted its stake in shares of BioScrip by 73.8% in the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock worth $115,000 after buying an additional 28,787 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of BioScrip during the second quarter worth about $123,000. Voya Investment Management LLC boosted its stake in shares of BioScrip by 41.4% in the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock worth $138,000 after buying an additional 14,867 shares in the last quarter. Finally, Alambic Investment Management L.P. purchased a new stake in shares of BioScrip during the first quarter worth about $160,000. Institutional investors and hedge funds own 84.15% of the company’s stock.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.